Amyloid-b (Ab) and hyperphosphorylated tau (p-tau) aggregates form the two discrete pathologies of Alzheimer disease (AD), and oligomeric assemblies of each protein are localized to synapses. To determine the sequence by which pathology appears in synapses, Ab and p-tau were quantified across AD disease stages in parietal cortex. Nondemented cases with high levels of AD-related pathology were included to determine factors that confer protection from clinical symptoms. Flow cytometric analysis of synaptosome preparations was used to quantify Ab and p-tau in large populations of individual synaptic terminals. Soluble Ab oligomers were assayed by a single antibody sandwich enzyme-linked immunosorbent assay. Total in situ Ab was elevated in patients with early-and late-stage AD dementia, but not in high pathology nondemented controls compared with age-matched normal controls. However, soluble Ab oligomers were highest in early AD synapses, and this assay distinguished early AD cases from high pathology controls. Overall, synapse-associated p-tau did not increase until late-stage disease in human and transgenic rat cortex, and p-tau was elevated in individual Ab-positive synaptosomes in early AD. These results suggest that soluble oligomers in surviving neocortical synaptic terminals are associated with dementia onset and suggest an amyloid cascade hypothesis in which oligomeric Ab drives phosphorylated tau accumulation and synaptic spread. These results indicate that antiamyloid therapies will be less effective once p-tau pathology is developed. (Am J Pathol 2016, 186: 185e198; http://dx
Ab has been highlighted as the primary toxin for loss of dendritic spines and synaptic function 13 and has also been directly linked to downstream tau pathology. For example, suppression of a tau kinase pathway can prevent Ab42 oligomer-induced dendritic spine loss, 14 and injection of Ab42 fibrils into mutant tau mice induces neurofibrillary tangles in cell bodies retrograde to the injections. 15 In vivo, effects of Ab oligomers versus fibrils are harder to separate; however, lowering soluble Ab oligomers by halving besite amyloid precursor protein (APP) cleaving enzyme reduces accumulation and phosphorylation of wild-type tau in a mouse model. 16 Evidence for Ab and tau association is particularly strong in the dendritic compartment, where tau was shown to mediate Ab toxicity via linkage of fyn to downstream N-methyl-D-aspartate receptor toxicity. 17 The earliest cognitive losses in AD have long been thought to correlate with synapse loss. 8,18e21 In humans, electron microscopic studies have documented synapse-associated Ab and tau, 22, 23 and much work documents activity-dependent release of synaptic Ab into interstitial fluid, which drives local Ab deposition in human subjects and in rodents. 4, 24, 25 Of importance, most synapse-associated Ab in cortical synapses of AD patients consists of soluble oligomeric species, 26 and synaptic tau pathology in AD also includes accumulations of SDS-stable tau oligomers. 27e31 With the use of synaptosomes (resealed nerve terminals) from the cortex of postmortem human subjects and a transgenic rat model of AD, the present experiments were aimed at determining the sequence of appearance of Ab and hyperphosphorylated tau (p-tau) pathology in synaptic terminals. In addition to early-and latestage disease, the AD samples included nondemented high pathology controls (HPCs) with substantial AD-related pathology. Synaptic accumulation of Ab occurred in the earliest plaque stages, before the appearance of synaptic p-tau, which did not appear until late-stage disease. Soluble Ab oligomers in synaptic terminals were elevated in early AD cases compared with HPCs, indicating an association with the onset of a dementia diagnosis.
Materials and Methods

Materials
The monoclonal anti-Ab antibody 10G4 is an N-terminal antibody with an epitope directed at residues 5 to 17 32 ; reactivity against human and rodent Ab was previously reported. 33 The anti-tau Ser396/404 phosphospecific PHF-1 antibody was a generous gift from Peter Davies (Albert Einstein College of Medicine, Bronx, NY). The conformation-dependent anti-Ab antibodies (prefibrillar oligomer-specific M55 and fibrilspecific M116) were a generous gift from Charles G. Glabe (University of California Irvine, Irvine, CA). The following antibodies were purchased: antiesynaptosomal-associated protein, 25 kDa (SNAP-25; Sternberger Monoclonals, Inc., Lutherville, MD), 4G8 anti-Ab (Senentek, Napa, CA), HT-7 anti-tau (Thermo Scientific, Rockford, IL), pS422 anti-tau Ser 422 phosphospecific (Invitrogen, Carlsbad, CA), and anti-synaptophysin (clone SY38) antibody (EMD Millipore, Billerica, MA). All isotype control mouse and rabbit IgG were purchased from BD Pharmingen (San Jose, CA). Recombinant Ab-40 peptide was purchased from US PEPTIde (Rancho Cucamonga, CA). Zenon isotype-specific IgG labeling kits, Alexa 488-conjugated chicken anti-mouse and Alexa 594-conjugated chicken anti-rabbit IgG were purchased from Molecular Probes (Eugene, OR). Horseradish peroxidase-conjugated anti-mouse IgG was from Jackson ImmunoResearch (West Grove, PA). Pierce high-sensitivity streptavidin-horseradish peroxidase, Supersignal West Femto substrate, and bicinchoninic acid protein assay kit were from Thermo Scientific, (Rockford, IL). 3,3 0 ,5,5 0 -Tetramethylbenzidine substrate was purchased from SigmaAldrich (St. Louis, MO).
Human Brain Specimens
Brain autopsy samples of parietal (A39 and A40), superior parietal (A7), and entorhinal cortex and hippocampus were obtained from the University of California Los Angeles (UCLA), University of Southern California, and University of California Irvine AD Research Centers. A total of 46 samples (25 women and 21 men) were used and were classified into groups on the basis of both clinical and pathologic criteria. Controls included four samples from cognitively normal elderly controls, two samples from spinocerebellar ataxia type II patients; 16 samples were from individuals without a clinical history of dementia but with histopathologic signs of AD-related pathology (HPCs); some of these subjects were cognitively impaired. Twentyfour samples were from individuals that were clinically demented and histopathologically diagnosed with AD; for the purpose of histologic staging, cases were classed as early versus late AD with the use of the Braak stage assignment. The mean age was 82 years for AD cases, and 90 years for normal and HPC cases. The mean postmortem interval was 6.9 hours for AD cases and 7 hours for normal and HPC cases. Detailed information about individual cases is presented in Table 1 . For cryopreservation, samples were minced and slowly frozen in isotonic sucrose on the day of autopsy as previously described 33 ; the same protocols were used at each of the three institutions that provided samples.
Animals
We used a transgenic rat model of AD described previously.
34e36 These animals are homozygous for the following three gene constructs: i) human APP 695 with the K670N/M671L mutation (rat synapsin-1 promoter); ii) human APP minigene with the K670N/M671L and V717F mutations (platelet-derived growth factor b promoter); and iii) human presenilin-1 with the M146V mutation (rat synapsin-1 promoter). This model exhibits age-associated Ab pathology, with sparse hippocampal plaques seen by 9 ajp.amjpathol.org -The American Journal of Pathology Flow Cytometric Analysis of Synaptosome-Enriched P-2 Fraction P-2 fractions (synaptosome-enriched fractions) were prepared from cryopreserved brain tissue as described previously, 37 cryopreserved in 0.32 mol/L buffered sucrose solution and stored at À80 C as aliquots. On the day of the experiment, aliquots were quickly defrosted at 37 C, and P-2 pellets were collected by centrifugation. After fixation in 0.25% paraformaldehyde/phosphate-buffered saline (PBS; 1 hour at 4 C), and permeabilization in 0.2% Tween20/PBS solution (15 minutes at 37 C), the pellets were incubated with Ab or tau/p-tauespecific antibodies, directly labeled with Alexa 488 or Alexa 647 fluorochromes with the use of Zenon isotype-specific labeling kits (30 minutes at room temperature). Immunolabeled P-2 pellets were washed with 0.2% Tween20/PBS and resuspended in 500 mL PBS for flow cytometric analysis. Data were acquired with the use of a BD-FACS Calibur analytical flow cytometer (Becton-Dickinson, San Jose, CA) equipped with argon 488 nm, heliumneon 635 nm, and helium-cadmium 325 nm lasers. Debris was excluded by establishing a size threshold set on forward light scatter. A total of 10,000 particles were collected and analyzed for each sample; an additional 5000 Ab-positive particles were collected for experiments that investigated Ab-positive synaptosomes. Alexa 488 and Alexa 647 were detected by FL-1 (fluorescein isothiocyanate) and FL-4 (allophycocyanin) channel photomultiplier tubes, respectively. Analysis was performed with the use of FCS Express software version 3 (DeNovo Software, ON, Canada).
Confocal Microscopy
Cryopreserved P-2 fractions were defrosted, fixed, and permeabilized as described in the section above. Fixed P-2 fractions were incubated with primary mouse anti-synaptophysin and conformation-dependent rabbit anti-Ab prefibrillar oligomer-specific M55 or anti-Ab fibril-specific M116 antibodies in 2% fetal bovine serum/PBS solution (2 hours at room temperature), followed by washing with 0.2%Tween20/PBS solution and incubation with Alexa 488-conjugated chicken anti-mouse and Alexa 594-conjugated chicken anti-rabbit IgG secondary (1 hour at room temperature). After washing, immunolabled P-2 fractions were dispersed with a pipette and spread on slides. Slides were dried, coverslipped with Vectashield mounting medium (Vector Laboratories Inc., Burlingame, CA), and stored at 4 C. Confocal fluorescence and differential interference contrast images of synaptosomes were performed with the use of a Leica TCS-SP2 confocal microscope (Heidelberg, Germany) with 63Â oil immersion objective (numerical aperture 1.2). The Alexa Fluor 488 and 594 fluorescent signals were captured with the use of sequential line scanning with double excitation of 488-nm line from argon laser and 594-nm line from helium-neon laser. Confocal pinhole was set to 1 Airey unit.
Oligomeric and Total Ab ELISA
To measure concentrations of the soluble Ab oligomers in human and rat synaptosome-enriched P-2 fractions, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) with the use of the same monoclonal anti-Ab antibody (10G4) as both the capture and reporter antibodies. High-bind 96-well ELISA plates were coated with unlabeled 10G4 antibody in 0.1 mol/L carbonate buffer, pH 9.6 (overnight at 4 C), followed by blocking with 4% bovine serum albumin in PBS (4 hours at room temperature). A 7-point standard curve (range from 1.95 to 125 ng/mL) (Supplemental Figure S1A ) was constructed with the use of photochemically cross-linked synthetic Ab40 oligomers, which were described previously. 38 The cross-linked oligomer standards remained stable in 0.1% 1,1,1,3,3,3-hexafluoro-2-proponol (Supplemental Figure S1A) , and the assay did not detect monomeric Ab (in 0.1% 1,1,1,3,3,3-hexafluoro-2-proponol) (Supplemental Figure S1B ). Specificity of the assay for oligomeric Ab species was also confirmed by measuring Ab oligomer concentration in the presence of the excess amount of monomeric Ab (Supplemental Figure S1B ). The assay's limit of detection was calculated as 7.48 ng/mL; the limit of quantitation was 20.63 ng/mL. Soluble P-2 fractions were extracted by sonication in PBS with protease inhibitors and then spun at 100,000 Â g for 30 minutes. The supernatant fluid was collected and used for the ELISA. Samples and standards were diluted in 1% bovine serum albumin in PBS and loaded into plates in duplicate (overnight at 4 C). After washing with PBS, biotinylated 10G4 antibody was applied (overnight at 4 C). The next day, plates were washed with PBS and incubated with streptavidinhorseradish peroxidase (1 hour at room temperature). The immunocomplex was reacted with 3,3 0 ,5,5 0 -tetramethylbenzidine substrate and was detected with the use of a Versamax microplate reader (Molecular Devices, Sunnyvale, CA). Concentrations of Ab oligomers in samples were calculated from the standard curve. ajp.amjpathol.org -The American Journal of Pathology Total Ab levels were measured with the use of a sandwich ELISA as described previously. 39 Concentrations of Ab oligomers and total Ab in each sample were normalized against the total protein concentration measured with the use of Pierce BCA Protein Assay Kit according to the manufacturer's protocol.
Statistical Analysis
Statistical analyses were performed with SPSS 16.0 for Mac (SPSS Inc., Chicago, IL). Comparisons of Ab and tau indices in human tissue between different neuropathologic stages of AD were analyzed by one-way analysis of variance. Additional post hoc comparisons were performed with Tukey's test, when applicable. Comparisons of Ab and tau indices between transgenic and wild-type rat tissue of different ages were analyzed with unpaired t-tests. Associations between Ab plaque density and total or oligomeric synaptic Ab levels were analyzed with Spearman's rank correlation coefficient. Comparisons of synaptic p-tau levels between the overall pool of synaptosomes and the Abpositive subset were conducted with paired t-tests.
Results
Total in Situ Synaptic Ab Is Associated with Plaque Level in Parietal Cortex
To study synaptic Ab pathology across disease stage, synaptosomes (resealed nerve terminals) were prepared from human parietal cortex samples cryopreserved at the time of autopsy; tissue was finely minced in isotonic sucrose, followed by slow freezing. Synaptosomes are primarily presynaptic and contain mitochondria, endosomes, and exocytotic structures 40 ; some postsynaptic elements are also present, with approximately 36% of particles positive for postsynaptic density protein 95. 37 Comparison of synaptosomal proteins with proteins in undisturbed brain slices has shown that synaptic bouton protein composition is maintained in synaptosomes. 41 Demographic and neuropathologic data for the normal control, HPC, and AD cases are shown in Table 1 . HPCs indicated substantial Ab and/or tau pathology but did not meet clinical criteria for dementia.
Using flow cytometry to focus the analysis on a large and pure population of synaptic terminals within the P-2 fraction, we first measured synaptic Ab levels across disease stages in human samples. To label intracellular antigens, samples were first lightly fixed, then permeabilized before immunolabeling with the N-terminal antibody 10G4; therefore total synaptic terminal Ab accumulation was measured in situ. Note that the protocol for fixation and immunolabeling includes multiple washes of the pellet in large volumes of PBS with 0.2% Tween, which would be expected to remove adherent artifactual Ab. In addition, incubation of P-2 samples with a combination of trypsin and heparinase before fixation did not reduce synaptic Ab labeling (Supplemental Figure S2, A and   B) . Previous work has shown that Ab-positive synaptosomes are also SNAP-25 positive, and, therefore, not Ab aggregates. 42 In addition, preaggregated Ab does not show up on flow dot plots, 43 and synaptosomes physically sorted on size show a uniform population of spherical particles without visible artifacts. 44 Representative dot plots from the flow cytometric analysis are shown in Figure 1 ; Ab immunofluorescence is plotted against forward scatter, which is proportional to particle size. Two variables are reported for the fluorescence of each sample: the size of the positive fraction (% positive) and the brightness of fluorescence (relative fluorescence unit). For each experiment, background labeling was determined with an isotype control antibody ( Figure 1A) , and positive control samples were immunolabeled for the presynaptic docking protein SNAP-25 ( Figure 1B) . Figure 1B shows the purity of the synaptosomal population examined (approximately 95%) when the rectangular analysis gate, based on size standards, is drawn to include only 
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The American Journal of Pathology -ajp.amjpathol.orgparticles between 0.75 and 1.5 mm. All flow cytometric data are routinely collected from this size-based (forward scatter) analysis gate to capture a relatively pure synaptosome population. We have extensively characterized 10G4 immunolabeling of synaptosomes and compared it with other Ab and APP antibodies; in contrast to 10G4, the APP antibody 3E9 strongly labels most synaptosomes in both control and AD samples. The bright-specific flow cytometric signal of 10G4 also contrasts with the poorer flow cytometric results with the use of 6E10, which does not label synaptosomes in situ above background, despite mapping to a similar epitope. Like 10G4, MOAB2, a new monoclonal antibody specific for intraneuronal Ab that does not label APP, 45 shows a strong specific signal for synaptic Ab with flow cytometric analysis (Supplemental Figure S2 , CeE). Taken together with evidence from Western blot analysis that 10G4 strongly labels high molecular weight aggregates, SDS-stable oligomers, and monomer in a pattern that resembles labeling by an Ab42-specific antibody, 26 these results indicate that, for flow cytometry, 10G4 is selective for aggregated Ab in situ. This interpretation is also supported by recent work showing that sequence-specific Figure 2 Synaptic Ab pathology across disease stage. A: Group data show total in situ synaptic Ab, measured by flow cytometry, plotted by Braak NFT stage. For Braak staging cases were divided into four groups: Con, HPC, AD IV, and AD ! V. B: The assigned NFT stage was plotted against plaque stage for each of the three groups' Cons, HPCs, and AD; HPCs are distributed across plaque stages. C and D: Total in situ Ab level measured by flow cytometry significantly correlates with the local plaque level in the parietal cortex, taken from the neuropathology report, when all samples are included (C) and for the HPC group considered alone (D). E: ELISA measurements of total soluble Ab in synaptosome-enriched P-2 samples across disease stage. F: Western blots with 6E10 antibody across disease stage in P-2 samples from parietal cortex. G: Soluble oligomeric Ab levels in parietal cortex P-2 samples plotted across Braak stages. Data are expressed as means AE SEM. n Z 6 Cons, n Z 12 HPCs, n Z 9 AD IV, and n Z 7 AD ! V (A); n Z 6 Cons, n Z 12 HPCs, and n Z 16 AD (B); n Z 34 samples (C); n Z 12 HPC samples (D); n Z 5 Cons, n Z 7 HPCs, n Z 4 AD IV, and n Z 6 AD ! V (E); controls n Z 6 Cons, n Z 12 HPCs, n Z 7 AD IV, and n Z 9 AD ! V (G). *P < 0.05, **P < 0.01. Ab, amyloid-b; AD, Alzheimer disease; AD IV, Braak stage I to IV; AD ! V, Braak stage V to VI; B, Braak stage; Con, control; ELISA, enzyme-linked immunosorbent assay; HPC, high pathology control; NFT, neurofibrillary tangle. ajp.amjpathol.org -The American Journal of Pathology anti-Ab antibodies are sensitive to conformation and differentially label aggregated Ab preparations. 46 As previously reported, synaptic terminals from control cases show little to no Ab immunolabeling ( Figure 1C ) 26, 33, 42, 47 ; representative plots from AD cases illustrate the rise in synaptic Ab with increasing neuropathologic disease stage and the degree to which synaptic terminal Ab increases between plaque stage 0 (no plaque deposition) and stage C (end-stage plaque deposition) (Figure 1, D and E ). 48 Figure 2A shows group differences in aggregate flow cytometric data [F(3,30) Z 6.13, P Z 0.002] in both early-stage (Braak II to IV) and late-stage (Braak V to VI) AD cases. Total in situ Ab level was increased above the control and HPC groups (P< 0.05), which were not different from each other. When all cases in the present study are plotted by assigned neurofibrillary tangle and plaque stages (Figure 2B ), the AD cases primarily cluster in the highest stage, and cognitively/neuropathologically normal control cases cluster in the lowest stage for both pathologies. However, the HPC cases are distributed across the four plaque stages, ranging from sparse to heavy plaque burden. The total in situ Ab level measured by flow cytometry was highly correlated with the plaque score assigned by the pathologist for parietal cortex, which was taken from the neuropathology report. The correlation was strong when all cases were included in the analysis (r s Z 0.67, P < 0.001) ( Figure 2C ) and when the HPC group was analyzed alone (r s Z 0.68, P Z 0.015) ( Figure 2D ). The progressive increase in total soluble synaptic Ab across disease stages was confirmed biochemically by ELISA [F(3,18) Z 4.91, P Z 0.01] (Figure 2E ) of the P-2 samples. These results indicate that in situ synaptic Ab is associated with the local appearance of neuritic plaques, particularly in HPC samples.
To confirm that flow cytometric increases are not related to APP, Western blot analysis of SDS-PAGE with the 6E10 antibody show large increases in Ab monomer and lesser changes in small (<50 kDa) oligomers with neuropathologic disease stage in P-2 fractions from parietal cortex ( Figure 2F) . Some of these bands may also represent APP fragments that contain the 6E10 epitope. Some oligomers between 10 and 100 kDa did not change with disease stage, particularly a tetrameric peptide. This result is consistent with previous work showing that the Ab42 tetramer structure is likely to be stable and long-lived and serves as a module for formation of larger Ab assemblies. 49 A prominent set of bands at approximately 55 kDa seems likely to include Ab*56. 
Synapse-Associated Soluble Oligomers Are Associated with Onset of Dementia
In the same groups of staged parietal cortex samples, we also measured soluble Ab oligomers (oAb) in synaptosomeenriched P-2 fractions by ELISA. This assay, based on protocols developed recently by others, 51e55 used the same antibody (10G4) for capture and detection and cross-linked oligomeric Ab40 for the standards. Synaptic oAb was markedly elevated in the early AD group relative to the neuropathologically normal (P Z 0.01) and HPC (P Z 0.05) groups [F(3,30) Z 4.13, P Z 0.015] ( Figure 2G ). oAb was also numerically higher in early AD than in late AD (71.3 AE 29 ng/mg protein), but this difference did not reach significance after adjusting for multiple comparisons (P Z 0.096). In contrast to total in situ Ab measured by flow cytometry, parietal cortex oAb did not correlate with Ab plaque counts from neuropathology reports (data not shown).
The sharp oAb elevation in early AD cases suggests that the clinical syndrome of AD dementia may emerge once the level 
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To confirm that synaptic Ab is oligomeric, P-2 samples were immunolabeled with conformation-dependent monoclonal antibodies and spread on slides for confocal microscopy. These novel monoclonal antibodies were derived from the well-characterized polyclonal A11 (prefibrillar oligomers) and OC antibodies (fibrillar oligomers); only the fibril-specific antibody M116 labels Ab deposits in the AD brain. 56 Characterization of these antibodies has shown a number of distinct subtypes within the prefibrillar and fibrillar classes of Ab oligomers, illustrating the diversity of Ab oligomers in the AD brain. 46 ,57 A subset of spheroid AD synaptosomes showed diffuse labeling for both prefibrillar (antibody M55) (Figure 3 Corresponding to human results, the ELISA for soluble oAb ( Figure 4F ) in transgenic rat P-2 samples also shows age and genotype effects with significant elevations in each age group, beginning at 3 months [age: F(2,53) Z 44.10, P < 0.001; genotype: F(1,35) Z 54.13, P < 0.001; age Â genotype interaction: F(2,35) Z 44.06, P < 0.001]. Importantly, subtle cognitive deficits are already detectable by 3 months of age in this model.
Synaptic p-Tau Is Not Elevated until Late-Stage AD in Parietal Cortex
Because tau and p-tau oligomers may contribute to synaptic dysfunction and loss, 8, 27, 29, 58 we next examined timing of the appearance of synaptic p-tau for disease stage and amyloid pathology using the set of staged human samples, including nondemented HPCs. P-2 samples were immunolabeled for tau with the use of three antibodies: one directed against total tau (HT7) and two specific for p-tau (PHF-1 and pS 422 ). The same immunolabeling protocols described above for flow Figure 5F ). HT7 antibody labels both phosphorylated and nonphosphorylated (total) tau; therefore, p-tau likely accounts for the increased HT7 fluorescence in latestage AD ( Figure 5D ).
Although overall synaptic p-tau level in the parietal cortex is not elevated until late-stage AD, some cases found relatively high levels of synaptic p-tau in the parietal cortex in earlystage neurofibrillary disease. Figure 5G shows representative flow cytometric data for one such Braak III case with high p-tau fluorescence in parietal cortex. No apparent association was found between higher p-tau levels and mixed pathology in the present study. These data indicate that, in some circumstances, advanced neocortical synaptic tau pathology may be seen in early-stage disease, before the cortical deposition of NFTs.
Synaptic p-Tau Follows Amyloid Pathology in Aged Transgenic APP/PS1 Rats in the Absence of Tau Mutation or Overexpression
Tau hyperphosphorylation has been long observed in a number of animal models of AD that express only amyloid Figure 5 Synaptic p-tau is not elevated until late-stage Alzheimer disease in parietal cortex. A, C, and E: Representative dot plots from the flow cytometric analysis are shown for p-tau labeling with the PHF-1 antibody; 10,000 synaptosomes are plotted for each sample; the FSC variable is proportional to size; percentage, positive fraction in analysis gate, RFU, mean relative fluorescence in analysis gate. B, D, and F: Aggregate plots of flow cytometric data from synaptosome-enriched P-2 samples from parietal cortex for total tau with HT-7 (B), and p-tau with PHF-1 (D), and pS 422 (F) across disease stages. Cases were divided into four groups: Cons, HPCs, AD IV, and AD ! V. G: Representative dot plot from flow cytometric analysis for an early Braak stage case with elevated p-tau signal in parietal cortex P-2. Data are expressed as means AE SEM. n Z 5 to 6 Cons, n Z 11 to 12 HPCs, n Z 9 AD IV, and n Z 8 to 9 AD ! V (B, D, and F). ***P < 0.001. AD, Alzheimer disease; AD IV, Braak I to IV; AD ! V, Braak V to VI; Con, control; FSC, forward scatter; HPC, high pathology control; p-tau, hyperphosphorylated tau; RFU, relative fluorescence unit. Figure 6 Synaptic p-tau follows amyloid pathology in a transgenic rat model of Alzheimer disease. AeC: Representative dot plots from the flow cytometric analysis are shown for background staining in the presence of isotype-specific control antibody (A), and p-tau immunolabeling with the PHF-1 antibody in a 20-month-old WT (B)] and Tg (C) P-2 samples. Ten thousand synaptosomes are plotted for each sample; the FSC variable is proportional to size; percentage, positive fraction in analysis gate, RFU, mean relative fluorescence in analysis gate. D: Group data for 3-, 9-, and 20-month-old animals; p-tau immunolabeling is shown for the PHF-1 in frontal cortex P-2 samples. Data are expressed as means AE SEM. n Z 8 animals per group. **P Z 0.01. FSC, forward scatter; p-tau, hyperphosphorylated tau; RFU, relative fluorescence unit; Tg, transgenic; WT, wild-type.
pathology, and several groups, including ours, have localized p-tau to synapses in such animal models. 22, 33, 59 With the use of cryopreserved cortex samples from the same transgenic rat age groups as above (3, 9, and 20 months), we investigated the association of synaptic p-tau with disease stage and amyloid pathology. P-2 samples were immunolabeled for p-tau; flow cytometric analyses are illustrated in Figure 6 , AeC and show a representative increase in synaptic PHF-1 fluorescence in transgenic relative to wild-type animals at 20 months. Aggregate group data are shown in Figure 6D . Synaptic PHF-1 labeling only found significant genotype differences at 20 months of age [t(13) Z À3.01, P Z 0.010]. However, no genotype effects were seen for synaptic pS 422 labeling. These findings are consistent with human results above; however, as previously observed in mouse models with only Ab mutations, 60,61 synaptic p-tau pathology in this rat model is less robust than that seen above in human disease.
P-Tau Immunolabeling Is Elevated in Individual Ab-Positive Synaptosomes in Early AD
If early synaptic Ab accumulation drives tau phosphorylation within terminals, synaptic p-tau should be higher in the population of terminals positive for Ab. To test this hypothesis, we dual-labeled human parietal cortex P-2 samples for Ab (10G4) and p-tau (PHF-1), and used flow cytometry to collect data from Ab-positive synaptosomes (5000 per sample). This experiment used cases with early-stage disease (Braak II to III), in which the mean synaptic p-tau level was not different from controls ( Figure 5) ; we also included hippocampus and entorhinal cortex samples as regions that are affected earlier by tau pathology. Figure 7 , AeC, illustrates the analysis for a single dual-labeled sample; Figure 7A shows the total PHF-1-positive fraction (10,000 events), and Figure 7B shows the analysis gate for collection of Abpositive terminals in the same sample (5000 events); note that for this analysis strategy only data from the Ab-positives were saved. P-tau immunofluorescence increased from 8.9% in the total sample (Figures 7A) to 21.5% when only Abpositives were included ( Figure 7C ). The aggregate data ( Figure 7D) found that p-tau immunofluorescence was elevated in the Ab-positive fraction relative to the total sample in all three regions examined, increasing more than twofold in each region [t(11) Z À6.15, P < 0.001], hippocampal [t(6) Z À5.99, P Z 0.001], and entorhinal cortex [t(5) Z À9.05, P < 0.001].
To further examine the relation, correlation analyses were performed; despite the increased PHF-1 labeling in Abpositives, the PHF-1 level in each sample was not strongly correlated with the Ab level for parietal cortex across all disease stages (r Z 0.20, n Z 30; not shown). Reasoning that terminal accumulation of Ab in mid-and late-stage disease might obscure a relation, we next included only parietal cortex samples with early-stage AD ( Braak IV), which likewise showed no significant association (r Z 0.33, n Z 20) (Figure 6E ). However, early-stage samples from hippocampus and entorhinal cortex, affected earlier in disease, found a strong correlation (r Z 0.92, n Z 10; P < 0.0001) ( Figure 7F ). On the basis of the data presented earlier, which establishes the early appearance of Ab compared with p-tau, this association is consistent with Abdriven induction of tau phosphorylation in synaptic terminals relatively early in the disease process.
Discussion
Multiple lines of evidence document that substantial proportions of cognitively intact elderly show abundant AD pathology on autopsy or substantial amyloid deposition by neuroimaging.
62e65 However, robust biochemical and The total synaptic Ab measured by flow cytometry in the present experiments includes all forms of Ab in synaptic terminals detectable by an N-terminal antibody in situ. In contrast, the oAb assay measures only oligomeric Ab extracted from synaptosome-enriched P-2 fractions into buffer. Because Western blot analysis of P-2 samples shows a strong signal for postsynaptic density protein 95, 26 it is possible that some of the Ab signal in P-2 samples arises from extracellular Ab bound to postsynaptic surface receptors, particularly heparan sulfate proteoglycan. 66 However, prior electron microscopic studies reported by our group and others document the spherical and primarily presynaptic structure of synaptosomes, 33, 40 and incubation of AD synaptosomes with a combination of trypsin and heparinase does not reduce Ab labeling. Confirmation of presynaptic localization of oligomers by electron microscope would be optimal; however, detection of intraneuronal, particularly oligomeric, Ab is limited by the technical difficulty of detecting Ab antigens, which are hydrophobic and difficult to detect by conventional immunocytochemical methods, especially in postmortem tissue. 67 On the basis of previous and current results, we posit that most synaptosomal Ab represents an intraterminal pool largely localized within endosomal and autophagic vesicles, consistent with a strong literature showing synaptic release of Ab 25, 68, 69 and disruption of autophagy in AD. Relatively few examples in the literature have found cellular or pathologic factors associated with cognitive protection in subjects with AD pathology. 73 A theory that altered synaptic structure or function may be a key factor for protection against AD-related cognitive decline is attractive for a number of reasons, in part because of the strong association of cognitive decline with synapse loss, and because established AD pathology localizes to either extracellular (plaques) or somatic (tangles) regions. Along this line, two groups have recently showed the relative preservation of synaptic markers in cortex from nondemented high AD pathology subjects. 74, 75 One of these studies included a discovery microarray approach that identified a number of proteins that are differentially expressed in such subjects, including APP binding protein and regulators of apoptosis, trafficking, cytoskeletal structure, and cell-cycle proteins. 74 Work by Perez-Nievas et al 75 showed more fibrillar and oligomer-positive Ab plaques, increased p-tau oligomers, and glial activation in demented compared with nondemented subjects with underlying AD pathology. In another study, low molecular weight SDSstable Ab oligomers were associated with the postsynaptic density in patients with Alzheimer dementia but not in nondemented HPCs. 76 Results are mixed for soluble Ab oligomers in cortical homogenates, but increased oligomers were reported in demented compared with HPC cases. 51 Our data come from synaptosome-enriched P-2 fractions with membrane cryopreservation, which would be expected to retain soluble oligomers; this is in contrast to typical homogenate samples, which are more dilute and represent multiple cell types and cellular compartments. In the present experiments, the concentration of synaptic oligomers was the only Ab measure to distinguish HPCs from early dementia cases. Although noting that this study is based on a relatively small set of cases, this observation signals an association between synaptic Ab oligomers and clinical diagnoses of dementia.
The correlation between total in situ synaptic Ab and local plaque levels in the parietal cortex could be explained by accumulation of insoluble Ab deposits in two sinks: an extracellular one in plaques and an intraterminal one within endosomes/autophagic vacuoles. After eventual loss and degradation of the synaptic terminal, the insoluble synaptic vacuole pool would then serve as a seed for a new extracellular deposit. This explanation would be consistent with our observation of a (nonsignificant) reduction of oAb in late-stage compared with early-stage disease and with the view that amyloid plaques are predominately a sink rather than a source for soluble Ab. 2 However, plaques could still serve as local reservoirs for small oligomers, operating with a dynamic equilibrium. 77 For the oAb assay, note that the sandwich ELISA may detect multiple Ab molecules bound to an unrelated carrier protein such as a proteoglycan; this possibility should be somewhat mitigated by the use of an aqueous soluble fraction without membranes or membrane fragments.
Because tau aggregates can transfer from one cell to another, some p-tau in synapses may enter from the extracellular compartment. 78, 79 However, considered together with the early appearance of Ab relative to p-tau, the marked increase in p-tau in individual Ab-positive synapses is consistent with a hypothesis that p-tau induction is directly driven by synaptic oAb; synaptic p-tau may then lead to anterograde and retrograde trans-synaptic spread of tau pathology. Such a hypothesis is supported by the following multiple lines of evidence: i) the exclusive initial appearance of Ab in the neocortex before dementia onset, which has extensive reciprocal projections with hippocampus and entorhinal cortex 48, 80 ; ii) the well-established regional propagation of tau pathology in human disease and animal models 79,81e83 ; iii) the observation that low
Amyloid-b Precedes p-Tau in AD Synapses
The American Journal of Pathology -ajp.amjpathol.orglevels of dimeric oAb from the AD cortex are sufficient for induction of tau phosphorylation and beaded dystrophic neurites 84 ; and iv) evidence to indicate tau intracellular protein misfolding can be transmitted by direct proteinprotein contact. 78 Indeed, such a prion-like mechanism of endogenous templated protein corruption was suggested as a common mechanism for multiple neurodegenerative diseases. 85 Additional Ab-mediated mechanisms may also contribute to propagation of AD pathology; for example, oligomer binding to membrane lipids or to a7 nicotinic cholinergic receptors might modulate the downstream signaling. 84, 86, 87 Our results suggest that effective therapies will need to target synaptic Ab oligomers and that antiamyloid therapies will be much less effective once synaptic p-tau pathology has developed, thus providing a potential explanation for the failure of amyloid-based trials. An additional important clinical implication is that therapies slowing Ab oligomer accumulation in the synaptic compartment will delay onset of dementia. Clarifying the precise mechanisms by which soluble Ab oligomers induce p-tau induction and contribute to synaptic dysfunction in early dementia is an important next step; the correspondence between our human and animal data suggest that this and related animal models will be useful for understanding the progress of synaptic pathology and for developing therapies to protect synaptic terminals.
